

Colitis Treatment Pipeline Review H1 2016

Global Colitis Drugs and Companies Pipeline Review H1 2016

PUNE, INDIA, August 29, 2016 /EINPresswire.com/ -- Summary

'[Colitis - Pipeline Review, H2 2016](#)', provides an overview of the Colitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Colitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colitis and features dormant and discontinued projects.

Complete report details @ <https://www.wiseguyreports.com/reports/619304-colitis-pipeline-review-h2-2016> □

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/619304-colitis-pipeline-review-h2-2016> □

Scope

- The report provides a snapshot of the global therapeutic landscape of Colitis
- The report reviews pipeline therapeutics for Colitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-

registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Colitis therapeutics and enlists all their major and minor projects
- The report assesses Colitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Colitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Colitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Colitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/619304-colitis-pipeline-review-h2-2016> □

Key points in table of content

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Colitis Overview 10

Therapeutics Development 11

Pipeline Products for Colitis - Overview 11

Pipeline Products for Colitis - Comparative Analysis 12

Colitis - Therapeutics under Development by Companies 13

Colitis - Therapeutics under Investigation by Universities/Institutes 15

Colitis - Pipeline Products Glance	16
Late Stage Products	16
Clinical Stage Products	17
Early Stage Products	18
Colitis - Products under Development by Companies	19
Colitis - Products under Investigation by Universities/Institutes	20
Colitis - Companies Involved in Therapeutics Development	21
Aerpio Therapeutics, Inc.	21
Akebia Therapeutics, Inc.	22
Amorepacific Corporation	23
Bayer AG	24
Bristol-Myers Squibb Company	25
Cosmo Pharmaceuticals S.p.A	26
Dr. Falk Pharma GmbH	27
EA Pharma Co Ltd	28
Euroscreen S.A.	29
Genfit SA	30
Immuron Limited	31
Innate Pharma S.A.	32
Peptinov SAS	33
Pfizer Inc.	34
Prokarium Limited	35
RDD Pharma Ltd.	36
Saniona AB	37
Synovo GmbH	38
Colitis - Therapeutics Assessment	39
Assessment by Monotherapy Products	39
Assessment by Target	40
Assessment by Mechanism of Action	42
Assessment by Route of Administration	44
Assessment by Molecule Type	46
Drug Profiles	48
AcTMP-1 - Drug Profile	48
Product Description	48
Mechanism Of Action	48
R&D Progress	48
AKB-4924 - Drug Profile	49
Product Description	49
Mechanism Of Action	49
R&D Progress	49
AKB-6899 - Drug Profile	50
Product Description	50
Mechanism Of Action	50

R&D Progress 50

AN-346 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Antibody for Colitis - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Antisense RNAi Oligonucleotides to Inhibit TNFalpha for Inflammatory Diseases and Colitis - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

APY-0201 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

BC-1215 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

BMS-986104 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

budesonide - Drug Profile 58

Product Description 58

Mechanism Of Action 58

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=619304

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/342156482>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.